BidaskClub Downgrades Integra Lifesciences (NASDAQ:IART) to Sell

BidaskClub downgraded shares of Integra Lifesciences (NASDAQ:IART) from a hold rating to a sell rating in a research report sent to investors on Saturday morning, BidAskClub reports.

Several other analysts have also issued reports on IART. TheStreet lowered Integra Lifesciences from an a- rating to a c+ rating in a research note on Thursday. Zacks Investment Research raised Integra Lifesciences from a hold rating to a buy rating and set a $65.00 target price on the stock in a research report on Monday, September 2nd. Oppenheimer upped their target price on Integra Lifesciences from $65.00 to $70.00 and gave the company an outperform rating in a research report on Thursday, July 25th. ValuEngine raised Integra Lifesciences from a sell rating to a hold rating in a research report on Friday. Finally, BTIG Research set a $70.00 target price on Integra Lifesciences and gave the company a buy rating in a research report on Wednesday, July 24th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the stock. The stock has an average rating of Hold and an average price target of $62.42.

NASDAQ:IART traded down $0.22 on Friday, reaching $55.73. The company’s stock had a trading volume of 683,000 shares, compared to its average volume of 330,544. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.82 and a current ratio of 2.76. The business’s 50-day moving average price is $60.53 and its two-hundred day moving average price is $56.16. The firm has a market cap of $4.79 billion, a PE ratio of 23.03, a PEG ratio of 1.73 and a beta of 1.10. Integra Lifesciences has a 1-year low of $42.14 and a 1-year high of $65.09.

Integra Lifesciences (NASDAQ:IART) last released its quarterly earnings data on Thursday, October 24th. The life sciences company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.03. The firm had revenue of $379.10 million for the quarter, compared to analyst estimates of $376.85 million. Integra Lifesciences had a return on equity of 16.79% and a net margin of 3.99%. The business’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.59 earnings per share. As a group, sell-side analysts expect that Integra Lifesciences will post 2.74 EPS for the current year.

In related news, insider Lisa Evoli sold 2,380 shares of the stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $63.00, for a total transaction of $149,940.00. Following the sale, the insider now owns 2,588 shares of the company’s stock, valued at $163,044. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Kenneth Burhop sold 6,656 shares of the stock in a transaction that occurred on Tuesday, July 30th. The stock was sold at an average price of $63.98, for a total value of $425,850.88. Following the sale, the vice president now directly owns 15,921 shares in the company, valued at approximately $1,018,625.58. The disclosure for this sale can be found here. Insiders sold 879,421 shares of company stock worth $53,619,825 in the last ninety days. 4.50% of the stock is owned by company insiders.

A number of large investors have recently modified their holdings of IART. Amundi Pioneer Asset Management Inc. acquired a new stake in Integra Lifesciences during the first quarter worth approximately $329,000. Zions Bancorporation N.A. grew its position in Integra Lifesciences by 5.9% during the second quarter. Zions Bancorporation N.A. now owns 4,359 shares of the life sciences company’s stock worth $243,000 after buying an additional 242 shares in the last quarter. First National Bank of Omaha grew its position in Integra Lifesciences by 2.5% during the second quarter. First National Bank of Omaha now owns 41,044 shares of the life sciences company’s stock worth $2,292,000 after buying an additional 1,001 shares in the last quarter. Diversified Trust Co grew its position in Integra Lifesciences by 16.3% during the second quarter. Diversified Trust Co now owns 18,622 shares of the life sciences company’s stock worth $1,040,000 after buying an additional 2,605 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund grew its position in Integra Lifesciences by 1.4% during the second quarter. Oregon Public Employees Retirement Fund now owns 28,654 shares of the life sciences company’s stock worth $1,600,000 after buying an additional 404 shares in the last quarter. 81.91% of the stock is currently owned by institutional investors and hedge funds.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Featured Story: What are different types of coverage ratios?

Analyst Recommendations for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.